Searchable abstracts of presentations at key conferences in endocrinology

ea0081rc2.4 | Rapid Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

Diagnostic value of basal cortisol level to predict adrenal insufficiency in patients treated with glucocorticoids during COVID-19: a single centre observational cohort study

Jensterle Mojca , Rakusa Matej , Vidmar Gaj , Janez Andrej , Kocjan Tomaž

Objective: During the current pandemic of COVID-19, many therapeutic protocols adopted high dose systemic glucocorticoids (GC) for treatment of moderate to severe respiratory insufficiency. The suppression of the hypothalamic┬ľpituitary┬ľadrenal axis by synthetic GC, even after a short treatment period, cannot be reliably predicted due to pathophysiological changes in cortisol dynamics in critically ill, inter-individual pharmacokinetic differences, and sensitivity var...

ea0056p188 | Bone ' Osteoporosis | ECE2018

Bone mineral density decline following denosumab discontinuation might not be attenuated with previous bisphosphonate therapy

Japelj Miha , Vidmar Gaj , Rajic Antonela Sabati , Pfeifer Marija , Kocjan Tomaz

Objective: Limited data suggest that the rebound increase in bone resorption and rapid bone mineral density (BMD) decline following sudden interruption of denosumab therapy can be avoided in patients previously treated with bisphosphonates. We aimed to compare BMD changes in osteoporotic patients after denosumab discontinuation regarding their previous bisphosphonate (BP) therapy.Material and methods: There were 14 women (age 69 years, BMI 23.1 kg/m...

ea0099rc11.1 | Rapid Communications 11: Adrenal and Cardiovascular Endocrinology | Part II | ECE2024

Changing clinical presentation of pheochromocytomas in a tertiary centre

Rakusa Matej , Vidmar Gaj , Silva Ludemila , Gerl Ursa , Kocjan Tomaž

Context: Pheochromocytomas and paragangliomas (PPGLs) are rare tumours with potentially harmful cardiovascular complications. Traditionally, they were detected in patients with symptoms and signs of catecholamine excess or during genetic surveillance. However, according to recent reports, PPGLs are increasingly being diagnosed in the setting of incidentally discovered adrenal masses.Aim: To assess the initial clinical presentation of our PPGL patients wi...

ea0049oc10.4 | Bone & Calcium Homeostasis | ECE2017

The effect of denosumab or bisphosphonates in women with severe postmenopausal osteoporosis after completion of teriparatide treatment

Kocjan Tomaz , Rajic Antonela Sabati , Sever Mojca Jensterle , Vidmar Gaj , Ostanek Barbara , Marc Janja , Orehek Nina , Pfeifer Marija

The ideal antiresorptive agent to preserve or further increase bone mineral density (BMD) following teriparatide treatment is not known. We aimed to compare BMD changes after one year of therapy with denosumab or bisphosphonates in osteoporotic patients who had completed treatment with teriparatide. We retrospectively analyzed 140 women (age 74 years, 26 years from menopause, BMI 27 kg/m2 on average) with severe postmenopausal osteoporosis who had been treated betwe...

ea0049gp39 | Bone & Calcium Homeostasis 1 | ECE2017

Association of changes in serum urate level and bone mineral density during treatment with teriparatide: a retrospective observational study

Kocjan Tomaz , Vidmar Gaj , Rajic Antonela Sabati , Jensterle Sever Mojca , Pfeifer Marija , Marc Janja , Orehek Nina , Ostanek Barbara

Serum urate level has recently been associated with increased bone mineral density (BMD). Teriparatide, an osteoanabolic medication for osteoporosis, is associated with increased incidence of hyperuricemia. Hence, we hypothesized that changes in serum urate are associated with changes in BMD and procollagen type 1 N-terminal propeptide (P1NP) during treatment with teriparatide.We collected data from 151 women (mean age 72 years, mean BMI 26.6 kg/m2<...